Nothing Special   »   [go: up one dir, main page]

Bhatnagar et al., 2017 - Google Patents

Potential role of Vδ2+ γδ T cells in regulation of immune activation in primary HIV infection

Bhatnagar et al., 2017

View HTML
Document ID
16463965304462317627
Author
Bhatnagar N
Girard P
Lopez-Gonzalez M
Didier C
Collias L
Jung C
Bollens D
Duvivier C
Von Platen C
Scott-Algara D
Weiss L
ANRS EP-56 Group
Publication year
Publication venue
Frontiers in Immunology

External Links

Snippet

Although conventional regulatory T cells (Tregs) are sufficient in controlling low residual T- cell activation in ART-treated patients, they are not efficient in controlling exaggerated immune activation associated with high levels of HIV replication in primary HIV infection …
Continue reading at www.frontiersin.org (HTML) (other versions)

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay
    • G01N33/569Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966Animal cells
    • G01N33/56972White blood cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0647Haematopoietic stem cells; Uncommitted or multipotent progenitors

Similar Documents

Publication Publication Date Title
Bhatnagar et al. Potential role of Vδ2+ γδ T cells in regulation of immune activation in primary HIV infection
Asano et al. PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy
Chase et al. Preservation of FoxP3+ regulatory T cells in the peripheral blood of human immunodeficiency virus type 1-infected elite suppressors correlates with low CD4+ T-cell activation
Fahey et al. Viral persistence redirects CD4 T cell differentiation toward T follicular helper cells
Peppa et al. Adaptive reconfiguration of natural killer cells in HIV-1 infection
Day et al. PD-1 expression on Mycobacterium tuberculosis-specific CD4 T cells is associated with bacterial load in human tuberculosis
Pitard et al. Long-term expansion of effector/memory Vδ2− γδ T cells is a specific blood signature of CMV infection
Forcade et al. Circulating T follicular helper cells with increased function during chronic graft-versus-host disease
Baecher-Allan et al. MHC class II expression identifies functionally distinct human regulatory T cells
Herrmann et al. Analysis of co-inhibitory receptor expression in COVID-19 infection compared to acute plasmodium falciparum malaria: lAG-3 and TIM-3 correlate with t cell activation and course of disease
Crellin et al. Human NKp44+ IL-22+ cells and LTi-like cells constitute a stable RORC+ lineage distinct from conventional natural killer cells
Kang et al. Defective control of latent Epstein-Barr virus infection in systemic lupus erythematosus
Vahlenkamp et al. Feline immunodeficiency virus infection phenotypically and functionally activates immunosuppressive CD4+ CD25+ T regulatory cells
Cunill et al. Follicular T cells from smB− common Variable immunodeficiency Patients are skewed Toward a Th1 Phenotype
Martin-Gayo et al. Circulating CXCR5+ CXCR3+ PD-1lo Tfh-like cells in HIV-1 controllers with neutralizing antibody breadth
Dean et al. Innate inflammation drives NK cell activation to impair Treg activity
Eken et al. Fingolimod alters tissue distribution and cytokine production of human and murine innate lymphoid cells
Lam et al. Co-infection of cytomegalovirus and Epstein-Barr virus diminishes the frequency of CD56dimNKG2A+ KIR− NK cells and contributes to suboptimal control of EBV in immunosuppressed children with post-transplant lymphoproliferative disorder
Kaminski et al. Characterization of a unique γδ T-cell subset as a specific marker of cytomegalovirus infection severity
Liu et al. Inverse correlation of Vδ2+ T‐cell recovery with EBV reactivation after haematopoietic stem cell transplantation
Chevalier et al. CD4 T-cell responses in primary HIV infection: interrelationship with immune activation and virus burden
Vivar et al. Survival and proliferation of CD28-T cells during HIV-1 infection relate to the amplitude of viral replication
Peng et al. Dynamic immune landscape and VZV-specific T cell responses in patients with herpes zoster and postherpetic neuralgia
Singh et al. Functional invariant natural killer T cells secreting cytokines are associated with non-progressive human immunodeficiency virus-1 infection but not with suppressive anti-retroviral treatment
Caldirola et al. Immune monitoring of patients with primary immune regulation disorders unravels higher frequencies of follicular T cells with different profiles that associate with alterations in B cell subsets